Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term evolution of multiple sclerosis disability in the treatment era.
University of California, San Francisco MS-EPIC Team:; Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL. University of California, San Francisco MS-EPIC Team:, et al. Among authors: goodin ds. Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13. Ann Neurol. 2016. PMID: 27464262 Free PMC article.
Therapeutic developments in multiple sclerosis.
Goodin DS. Goodin DS. Expert Opin Investig Drugs. 2000 Apr;9(4):655-70. doi: 10.1517/13543784.9.4.655. Expert Opin Investig Drugs. 2000. PMID: 11060700 Review.
Neuromyelitis optica.
Cree BA, Goodin DS, Hauser SL. Cree BA, et al. Among authors: goodin ds. Semin Neurol. 2002 Jun;22(2):105-22. doi: 10.1055/s-2002-36534. Semin Neurol. 2002. PMID: 12524556 Review.
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.
Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL; Multiple Sclerosis Genetics Group. Barcellos LF, et al. Among authors: goodin ds. Am J Hum Genet. 2003 Mar;72(3):710-6. doi: 10.1086/367781. Epub 2003 Jan 28. Am J Hum Genet. 2003. PMID: 12557126 Free PMC article.
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Frohman EM, et al. Among authors: goodin ds. Neurology. 2003 Sep 9;61(5):602-11. doi: 10.1212/01.wnl.0000082654.99838.ef. Neurology. 2003. PMID: 12963748
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2003 Nov 25;61(10):1332-8. doi: 10.1212/01.wnl.0000095425.84407.39. Neurology. 2003. PMID: 14638950 Review.
194 results